Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 17/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 7/20 | 0.50 |
| ▸ | PTPRC | P08575 | 3/20 | 0.41 |
| ▸ | PTPRB | P23467 | 2/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | CDC25A | P30304 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7194695 | 0.94 | PTPN1 (0.53) | PTPN1PTPN2PTPRCPTPRBPTPN6 | |
| SCHEMBL7194653 | 0.94 | PTPN1 (0.53) | PTPN1PTPN2PTPRCPTPRBPTPN6 | |
| SCHEMBL7187785 | 0.84 | PTPN1 (0.54) | PTPN1PTPN2PTPRCPTPN6PTPN11 | |
| SCHEMBL7187658 | 0.84 | PTPN1 (0.66) | PTPN1PTPN2PTPRC | |
| SCHEMBL7192783 | 0.83 | PTPN1 (0.56) | PTPN1PTPN2PTPRCPTPRBPTPN6 | |
| SCHEMBL7594613 | 0.83 | PTPN1 (0.57) | PTPN1PTPN2PTPRCPTPN6PTPN11 | |
| SCHEMBL7194654 | 0.83 | PTPN1 (0.41) | PTPN1PTPN2PTPRC | |
| SCHEMBL7599748 | 0.82 | PTPN1 (0.65) | PTPN1PTPN2PTPRC | |
| SCHEMBL7659253 | 0.82 | PTPN1 (0.70) | PTPN1PTPN2PTPRC | |
| SCHEMBL7659065 | 0.82 | PTPN1 (0.56) | PTPN1PTPN2PTPRCPTPN6PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6498151-B2 | PROTEIN TYROSINE PHOSPHATASES INHIBITORS, ESPECIALLY AS ANTIDIABETIC AGENTS | MERCK FROSST CANADA & CO. (CA) | 2002-12-24 | — | — | US | claimed |
| US-6498151-B2 | PROTEIN TYROSINE PHOSPHATASES INHIBITORS, ESPECIALLY AS ANTIDIABETIC AGENTS | MERCK FROSST CANADA & CO. (CA) | 2002-12-24 | — | — | US | disclosed |
| US-20020091104-A1 | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091104-A1 | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors | PTPRF, PTPRS, PTPRO | PTPN1 13/4885PTPN2 24/4885PTPRC 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.